EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Improvement in Cutaneous Lupus Erythematosus After Twenty Weeks of Belimumab Use: A Systematic Review and Meta‐Analysis

Rachel Kneeland iD, Daniel Montes, Justin Endo, Bridget Shields, Christie M Bartels iD, Shivani Garg iD

Arthritis Care & Research · 2023

DOI: 10.1002/acr.25058 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Arthritis Care & Research, 2023. Verfasst von Rachel Kneeland und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Wisconsin School of Medicine and Public Health, Madison. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Lupus Erythematosus, Cutaneous. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Cutaneous lupus erythematosus (CLE), with or without systemic lupus erythematosus (SLE), can be debilitating and cause psychological distress. Belimumab, a monoclonal antibody that inhibits B cell activation, is a Federal Drug Administration–approved SLE medication, but less is known on its use in CLE. Moreover, the time to response after starting belimumab in CLE is unknown, which may lead to premature discontinuation in the absence of early perceivable benefits. Thus, the objectives of this meta‐analysis were to examine the efficacy of belimumab, as well as the time to response after starting belimumab in patients with CLE with or without SLE.

Methods

A comprehensive literature search was performed to include studies that examined clinical response in patients with CLE with or without SLE receiving belimumab. A clinical response at 52 weeks in belimumab users versus nonusers was summarized in a random‐effects model. Additionally, we calculated the pooled odds ratio (OR) for each consecutive 4‐week observation interval to identify time to a clinical response in CLE with or without SLE after starting belimumab.

Results

Among 747 screened studies, 14 were included. The pooled odds of clinical response at 52 weeks in belimumab users were 44% higher compared to nonusers (OR 1.44 [95% confidence interval (95% CI) 1.20–1.74], I 2 = 0%). A clinical response was first noted after 20 weeks of starting belimumab (OR 1.35 [95% CI 1.01–1.81], I 2 = 0%), with a sustained clinical response through 1 year.

Conclusion

The findings support belimumab as an effective therapy for CLE with SLE. Likewise, the findings inform patient counseling regarding estimates of 20 weeks to achieve a response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicLupus Erythematosus, CutaneousHumansTreatment OutcomeSeverity of Illness IndexImmunosuppressive AgentsAntibodies, Monoclonal, Humanized

Substanzen

Immunosuppressive AgentsbelimumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • University of Wisconsin School of Medicine and Public Health, Madison.

ORCID-Profile: Rachel Kneeland, Christie M Bartels, Shivani Garg

Zitieren

APA

Kneeland, R., Montes, D., Endo, J., Shields, B., Bartels, C. M., & Garg, S. (2023). Improvement in Cutaneous Lupus Erythematosus After Twenty Weeks of Belimumab Use: A Systematic Review and Meta‐Analysis. Arthritis Care & Research. https://doi.org/10.1002/acr.25058

Vancouver

Kneeland R, Montes D, Endo J, Shields B, Bartels CM, Garg S. Improvement in Cutaneous Lupus Erythematosus After Twenty Weeks of Belimumab Use: A Systematic Review and Meta‐Analysis. Arthritis Care & Research. 2023. doi:10.1002/acr.25058

BibTeX
@article{Kneeland2023,
  author = {Kneeland, Rachel and Montes, Daniel and Endo, Justin and Shields, Bridget and Bartels, Christie M and Garg, Shivani},
  title = {Improvement in Cutaneous Lupus Erythematosus After Twenty Weeks of Belimumab Use: A Systematic Review and Meta‐Analysis},
  journal = {Arthritis Care & Research},
  year = {2023},
  doi = {10.1002/acr.25058}
}
Kostenlos starten →